Most of the intended management changes after68Ga-DOTATATE PET/CT are implemented

Jeremie Calais, Johannes Czernin, Matthias Eiber, Wolfgang P. Fendler, Jeannine Gartmann, Anthony P. Heaney, Andrew E. Hendifar, Joseph R. Pisegna, J. Randolph Hecht, Edward M. Wolin, Roger Slavik, Pawan Gupta, Andrew Quon, Christiaan Schiepers, Martin S. Allen-Auerbach, Ken Herrmann

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

In this prospective referring-physician–based survey, we investigated the definite clinical impact of 68Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs). Methods: We prospectively studied 130 patients with 68Ga-DOTATATE PET/ CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the imaging report to denote intended management changes (Q2), and one 6 mo later (Q3) to verify whether intended changes were in fact implemented. To further validate the Q3 responses, a systematic electronic chart review was conducted. Results: All 3 questionnaires were completed by referring physicians for 96 of 130 patients (74%). 68Ga-DOTATATE PET/CT resulted in intended management changes (Q2) in 48 of 96 patients (50%). These changes were finally implemented (Q3) in 36 of 48 patients (75%). Q3 responses were confirmed in all patients with an available electronic chart (36/96; 38%). Conclusion: This prospective study confirmed a significant impact of 68Ga-DOTATATE PET/CT on the intended management of patients with NETs (50% of changes) and notably demonstrated a high implementation rate (75%) of these intended management changes.

Original languageEnglish (US)
Pages (from-to)1793-1796
Number of pages4
JournalJournal of Nuclear Medicine
Volume58
Issue number11
DOIs
StatePublished - Nov 1 2017

    Fingerprint

Keywords

  • DOTATATE
  • Impact on implemented management
  • Neuroendocrine tumors
  • PET/ CT
  • Somatostatin receptor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Calais, J., Czernin, J., Eiber, M., Fendler, W. P., Gartmann, J., Heaney, A. P., Hendifar, A. E., Pisegna, J. R., Randolph Hecht, J., Wolin, E. M., Slavik, R., Gupta, P., Quon, A., Schiepers, C., Allen-Auerbach, M. S., & Herrmann, K. (2017). Most of the intended management changes after68Ga-DOTATATE PET/CT are implemented. Journal of Nuclear Medicine, 58(11), 1793-1796. https://doi.org/10.2967/jnumed.117.192450